Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Intravenous Exatecan Mesylate (DX-891F) Administered Daily For Five Days Every Three Weeks To Patients With Previously Untreated Metastatic Gastric Cancer

NCT00017212 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00017212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00017212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Intravenous Exatecan Mesylate (DX-891F) Administered Daily For Five Days Every Three Weeks To Patients With Previously Untreated Metastatic Gastric Cancer
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2001
Completion date
September 30, 2003
Enrollment
Not reported
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastric cancer